<it>Bacillus Coagulans </it>GBI-30 (BC30) improves indices of <it>Clostridium difficile</it>-Induced colitis in mice
<p>Abstract</p> <p>Background</p> <p>Probiotics have beneficial effects in rodent models of <it>Clostridium difficile </it>(<it>C. diffiicle</it>)-induced colitis. The spore forming probiotic strain <it>Bacillus Coagulans </it>GBI-30,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-10-01
|
| Series: | Gut Pathogens |
| Subjects: | |
| Online Access: | http://www.gutpathogens.com/content/3/1/16 |
| _version_ | 1819043782561103872 |
|---|---|
| author | Fitzpatrick Leo R Small Jeffrey S Greene Wallace H Karpa Kelly D Keller David |
| author_facet | Fitzpatrick Leo R Small Jeffrey S Greene Wallace H Karpa Kelly D Keller David |
| author_sort | Fitzpatrick Leo R |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Probiotics have beneficial effects in rodent models of <it>Clostridium difficile </it>(<it>C. diffiicle</it>)-induced colitis. The spore forming probiotic strain <it>Bacillus Coagulans </it>GBI-30, 6086 (BC30) has demonstrated anti-inflammatory and immune-modulating effects <it>in vitro</it>. Our goal was to determine if BC30 improved <it>C. difficile</it>-induced colitis in mice. Starting on study day 0, female C57BL/6 mice were dosed by oro-gastric gavage for 15 days with vehicle (saline) or BC30 (2 × 10<sup>9 </sup>CFU per day). Mice in the <it>C. difficile </it>groups received an antibiotic mixture (study days 5 to 8 in the drinking water), and clindamycin (10 mg/kg, i.p., on study day 10). The <it>C. difficile </it>strain VPI 10463 was given by gavage at 10<sup>4 </sup>CFU to induce colitis on day 11. On day 16, stools and colons were collected for further analyses.</p> <p>Results</p> <p>All mice treated with BC30 survived on study day 13, while two mice treated with vehicle did not survive. On day 12, a significant difference (p = 0.0002) in the percentage of mice with normal stools (66.7%) was found in the BC30/<it>C. difficile </it>group, as compared to the vehicle/<it>C. diffcile </it>group (13.0%). On study day 16, 23.8% of mice treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0187). On this day, the stool consistency score for the BC30/<it>C. difficile </it>group (1.1 ± 0.2) was significantly lower (p < 0.05) than for the vehicle/<it>C. difficile </it>cohort (1.9 ± 0.2). BC30 modestly attenuated the colonic pathology (crypt damage, edema, leukocyte influx) that was present following <it>C. difficile infection</it>. Colonic MIP-2 chemokine contents (pg/2 cm colon) were: 10.2 ± 0.5 (vehicle/no <it>C. difficile</it>), 24.6 ± 9.5 (vehicle/<it>C. difficile</it>) and 16.3 ± 4.3 (BC30/<it>C. difficle</it>).</p> <p>Conclusion</p> <p>The probiotic BC30 improved some parameters of <it>C. difficile</it>-induced colitis in mice. BC30 prolonged the survival of <it>C. diffiicle </it>infected mice. Particularly, this probiotic improved the stool consistency of mice, in this infectious colitis model.</p> |
| first_indexed | 2024-12-21T10:02:15Z |
| format | Article |
| id | doaj.art-5af6703de1bc4431823aeccd1a9b6af7 |
| institution | Directory Open Access Journal |
| issn | 1757-4749 |
| language | English |
| last_indexed | 2024-12-21T10:02:15Z |
| publishDate | 2011-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Gut Pathogens |
| spelling | doaj.art-5af6703de1bc4431823aeccd1a9b6af72022-12-21T19:07:55ZengBMCGut Pathogens1757-47492011-10-01311610.1186/1757-4749-3-16<it>Bacillus Coagulans </it>GBI-30 (BC30) improves indices of <it>Clostridium difficile</it>-Induced colitis in miceFitzpatrick Leo RSmall Jeffrey SGreene Wallace HKarpa Kelly DKeller David<p>Abstract</p> <p>Background</p> <p>Probiotics have beneficial effects in rodent models of <it>Clostridium difficile </it>(<it>C. diffiicle</it>)-induced colitis. The spore forming probiotic strain <it>Bacillus Coagulans </it>GBI-30, 6086 (BC30) has demonstrated anti-inflammatory and immune-modulating effects <it>in vitro</it>. Our goal was to determine if BC30 improved <it>C. difficile</it>-induced colitis in mice. Starting on study day 0, female C57BL/6 mice were dosed by oro-gastric gavage for 15 days with vehicle (saline) or BC30 (2 × 10<sup>9 </sup>CFU per day). Mice in the <it>C. difficile </it>groups received an antibiotic mixture (study days 5 to 8 in the drinking water), and clindamycin (10 mg/kg, i.p., on study day 10). The <it>C. difficile </it>strain VPI 10463 was given by gavage at 10<sup>4 </sup>CFU to induce colitis on day 11. On day 16, stools and colons were collected for further analyses.</p> <p>Results</p> <p>All mice treated with BC30 survived on study day 13, while two mice treated with vehicle did not survive. On day 12, a significant difference (p = 0.0002) in the percentage of mice with normal stools (66.7%) was found in the BC30/<it>C. difficile </it>group, as compared to the vehicle/<it>C. diffcile </it>group (13.0%). On study day 16, 23.8% of mice treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0187). On this day, the stool consistency score for the BC30/<it>C. difficile </it>group (1.1 ± 0.2) was significantly lower (p < 0.05) than for the vehicle/<it>C. difficile </it>cohort (1.9 ± 0.2). BC30 modestly attenuated the colonic pathology (crypt damage, edema, leukocyte influx) that was present following <it>C. difficile infection</it>. Colonic MIP-2 chemokine contents (pg/2 cm colon) were: 10.2 ± 0.5 (vehicle/no <it>C. difficile</it>), 24.6 ± 9.5 (vehicle/<it>C. difficile</it>) and 16.3 ± 4.3 (BC30/<it>C. difficle</it>).</p> <p>Conclusion</p> <p>The probiotic BC30 improved some parameters of <it>C. difficile</it>-induced colitis in mice. BC30 prolonged the survival of <it>C. diffiicle </it>infected mice. Particularly, this probiotic improved the stool consistency of mice, in this infectious colitis model.</p>http://www.gutpathogens.com/content/3/1/16<it>Clostridium difficile</it>probioticscolitismice |
| spellingShingle | Fitzpatrick Leo R Small Jeffrey S Greene Wallace H Karpa Kelly D Keller David <it>Bacillus Coagulans </it>GBI-30 (BC30) improves indices of <it>Clostridium difficile</it>-Induced colitis in mice Gut Pathogens <it>Clostridium difficile</it> probiotics colitis mice |
| title | <it>Bacillus Coagulans </it>GBI-30 (BC30) improves indices of <it>Clostridium difficile</it>-Induced colitis in mice |
| title_full | <it>Bacillus Coagulans </it>GBI-30 (BC30) improves indices of <it>Clostridium difficile</it>-Induced colitis in mice |
| title_fullStr | <it>Bacillus Coagulans </it>GBI-30 (BC30) improves indices of <it>Clostridium difficile</it>-Induced colitis in mice |
| title_full_unstemmed | <it>Bacillus Coagulans </it>GBI-30 (BC30) improves indices of <it>Clostridium difficile</it>-Induced colitis in mice |
| title_short | <it>Bacillus Coagulans </it>GBI-30 (BC30) improves indices of <it>Clostridium difficile</it>-Induced colitis in mice |
| title_sort | it bacillus coagulans it gbi 30 bc30 improves indices of it clostridium difficile it induced colitis in mice |
| topic | <it>Clostridium difficile</it> probiotics colitis mice |
| url | http://www.gutpathogens.com/content/3/1/16 |
| work_keys_str_mv | AT fitzpatrickleor itbacilluscoagulansitgbi30bc30improvesindicesofitclostridiumdifficileitinducedcolitisinmice AT smalljeffreys itbacilluscoagulansitgbi30bc30improvesindicesofitclostridiumdifficileitinducedcolitisinmice AT greenewallaceh itbacilluscoagulansitgbi30bc30improvesindicesofitclostridiumdifficileitinducedcolitisinmice AT karpakellyd itbacilluscoagulansitgbi30bc30improvesindicesofitclostridiumdifficileitinducedcolitisinmice AT kellerdavid itbacilluscoagulansitgbi30bc30improvesindicesofitclostridiumdifficileitinducedcolitisinmice |